A device using next-gen technology to automatically deliver insulin was found to be more effective at maintaining blood glucose levels than standard-of-care management for type 1 diabetes.
A new device, which doesn’t rely on immunosuppressing drugs, may assist efforts to develop an artificial pancreas to treat diabetes.
This overview introduces connected and continuous glucose sensing technologies, smart insulin delivery systems and more innovations that help patients and doctors monitor and manage glucose levels and guide decision-making in diabetes care.
More than 15 billion batteries are sent to landfill sites every year – technology that converts glucose and oxygen into electricity has the potential to reduce this waste and serve as a sustainable alternative power source for medical devices.
Researchers pinpoint a sound-sensitive mammalian protein that lets them activate brain, heart or other cells with ultrasound.
Drug delivery, blood extraction, contrast agent injection – many procedures in modern medicine would be utterly impossible without needles. Despite the benefits, inserting pointy metal tubes into a patient also comes with several drawbacks. By downscaling the to micrometer-size, Japanese researchers open even more areas of application for needles, while bypassing some of the most important…
Heart failure with preserved ejection fraction was previously considered largely untreatable. A research team at the Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC) led by Professor Michael Gotthardt has now succeeded for the first time in improving cardiac function with the help of a synthetic nucleic acid, as the researchers report in the journal Science…
New coatings on implants could help make them more compatible. Researchers at the Martin Luther University Halle-Wittenberg (MLU) have developed a new method of applying anti-inflammatory substances to implants in order to inhibit undesirable inflammatory reactions in the body. Their study was recently published in the "International Journal of Molecular Sciences".
The world’s first licensed, downloadable artificial pancreas app for people with type 1 diabetes now launched, based on over a decade of research by Professor Roman Hovorka at the University of Cambridge and Cambridge University Hospitals NHS Foundation Trust. The CamAPS FX app works with an insulin pump and a glucose monitor to automatically deliver insulin to people living with the condition…
Treating type 1 diabetes and some cases of type 2 diabetes has long required painful and frequent insulin injections or a mechanical insulin pump for insulin infusion. But researchers from the University of North Carolina and NC State have now developed what could be a much more patient-friendly option: artificial cells that automatically release insulin into the bloodstream when glucose levels…
Researchers have identified a mechanism that allows cancer cells to respond and grow rapidly when levels of sugar in the blood rise. This may help to explain why people who develop conditions in which they have chronically high sugar levels in their blood, such as obesity, also have an increased risk of developing certain types of cancer.
Scientists have evidence that Popeye was right: Spinach makes you stronger. But it’s the high nitrate content in the leafy greens — not the iron — that creates the effect.
Painful insulin injections could become a thing of the past for the millions of Americans who suffer from diabetes, thanks to a new invention from researchers at the University of North Carolina and NC State, who have created a “smart insulin patch” that can detect increases in blood sugar levels and secrete doses of insulin into the bloodstream whenever needed.
The focus of the 2015 Diabetes Congress held in Berlin this May was ‘Personalised diabetes treatment: innovative – individual – sustained’. EH reports on points aired during the supporting press briefing. Report: Bettina Döbereiner
Anja Behringer reports on a neglected risk factor. With an aging population multimorbidity is increasingly a major challenge for hospital care. Diabetes is one of the medical conditions frequently encountered in multimorbid patients since cardiac and vascular diseases are often accompanied by dysfunctions of the blood sugar metabolism.
For three years the SWEET project, funded by the EU and the International Society for Paediatric and Adolescent Diabetes (ISPAD), has been preparing the establishment of centres of reference (CORs) for childhood diabetes. Now, the first 12 European CORs that are certified by SWEET have joined forces to promote improved cross-border cooperation in the treatment of young Type 1 and Type 2 diabetics.
Two small randomised trials published on bmj.com suggest that closed loop insulin delivery (also referred to as an artificial pancreas) may improve overnight blood glucose control and reduce the risk of nocturnal hypoglycaemia in adults with type 1 diabetes.
Although there is still disagreement as to ‘how’, when it comes to the question of whether the glucose level affects the prognosis for intensive care patients, the answer is a definite ‘yes’. ‘
In November, European diabetologists converged on Leverkusen, Germany, to discuss current practices in diabetic management of Type 1 and Type 2 in adults, as well as new technologies, procedures and the need for patients’ education.
7,000 people from 120 countries met in Stockholm this September to hear international experts discuss the progress, solutions and challenges of one of our greatest healthcare burdens. Prevention, self-monitoring, surgery, guidelines, economic problems, drug-safety, and co-morbidities – these are just a few of the problems associated with the care of about 55 million diabetics in Europe.
In 2009, the continuous glucose monitoring (CGM) market earned manufacturers $23.5; this is forecast to reach $52.0 million in 2016, according to a new analysis from Frost and Sullivan (F&S). For the study the markets covered by region are Benelux, Germany, France, Italy, Scandinavia, Spain and the United Kingdom.
Since February 2008, the Federal Joint Committee (G-BA) has been trying to exclude short acting insulin analogues completely from reimbursement by the statutory medical insurers. Why? Insulin analogues are 30% more expensive than human insulin.
The fact that child diabetics (type I) in Russia do not receive necessary and qualitative therapy was again highlighted during the 7th Russian conference 'The priority national project - Health - and the tasks of children's endocrinologists' held in Saint-Petersburg this June.
Type 1 diabetes is a life-long autoimmune disease with onset in early childhood. The diagnosis will initially turn the everyday life of children and their families topsy-turvy due to blood glucose testing, insulin injections, thorough calculation of meals, etc. It takes time before all these new and often frightening procedures become part of the daily routine of small diabetics.
ESC speaker John Cleland from the University of Hull, UK, sumed up the latest treatment available for patients with diabetes mellitus and expressed his worries about side-effects and efficacy of available anti-diabetic drugs. If you want to read his ESC abstract, just click the “read more” button.
Despite Hurricane Amma storming over Prague, hundreds of medical specialists paid little attention when they attended the 1st International Conference on Advanced Technologists and Treatments for Diabetes (ATTD), observed our Russian correspondent Olga Ostrovskaya, reporting on the International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Prague (ATTD) held in…
Presented during a symposium at Langenbeck-Virchow-Haus, in Berlin, the European CLINICIP research project aims to develop a method to improve glycaemic control during intensive care and provide a low-risk monitoring and control system that can control the metabolism of the critically ill
It occupies approximately the same space as one to three atoms.